4basebio (LON:4BB) Insider Heikki Lanckriet Acquires 2,000 Shares

Key Points

• Insider Heikki Lanckriet of 4basebio PLC purchased 2,000 shares at an average price of GBX 749 per share, totaling £14,980, on September 29th.
• The stock price increased on September 30th, reaching GBX 795, amidst a trading volume of 2,445 shares.
• 4basebio reported an earnings per share (EPS) of GBX (50) for the quarter, with analysts predicting an average EPS of -3.43 for the current year.

4basebio PLC (LON:4BB - Get Free Report) insider Heikki Lanckriet acquired 2,000 shares of the company's stock in a transaction that occurred on Monday, September 29th. The shares were acquired at an average price of GBX 749 per share, for a total transaction of £14,980.

4basebio Stock Performance

LON 4BB traded up GBX 65 on Tuesday, hitting GBX 795. The stock had a trading volume of 2,445 shares, compared to its average volume of 1,211. 4basebio PLC has a one year low of GBX 704.50 and a one year high of GBX 1,500. The company has a quick ratio of 3.52, a current ratio of 2.73 and a debt-to-equity ratio of 201.47. The stock has a market cap of £123.11 million, a price-to-earnings ratio of -845.74 and a beta of 1.09. The company's 50-day moving average is GBX 884.80 and its two-hundred day moving average is GBX 1,016.05.

4basebio (LON:4BB - Get Free Report) last posted its earnings results on Monday, September 29th. The company reported GBX (50) EPS for the quarter. On average, analysts expect that 4basebio PLC will post -3.43 earnings per share for the current year.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.